Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
The Hunt & Hess scale grades subarachnoid hemorrhage (SAH) severity from I to V based on clinical presentation. It is the most widely used SAH grading system, predicting surgical risk and mortality. Lower grades have better prognosis and are candidates for early surgical intervention.
Formula: Grade I–V based on clinical presentation. Predicts surgical mortality: I (~1%), II (~5%), III (~19%), IV (~42%), V (~77%).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Observe the patient's level of consciousness, severity of headache, presence of meningeal signs (nuchal rigidity, photophobia), and neurological deficits. Grade before sedation or intubation whenever possible, as these confound clinical assessment.
Grade I: mild headache or nuchal rigidity, no neurological deficit. Grade II: moderate-to-severe headache, nuchal rigidity, no deficit beyond CN palsy. Grade III: drowsiness, confusion, or mild focal deficit. Grade IV: stupor, moderate-to-severe hemiparesis, early decerebrate posturing. Grade V: deep coma, decerebrate rigidity, moribund appearance.
Grades I–III generally proceed to early aneurysm securement (surgical clipping or endovascular coiling within 24 hours) with lower surgical risk. Grades IV–V carry substantially higher risk — management is individualized, balancing risk of rebleeding against operative risk in a compromised patient.
Emergency physicians, neurosurgeons
Immediate Hunt-Hess grading on arrival establishes clinical severity, communicates the urgency of neurosurgical consultation, and guides the pace of further workup (CT, LP, CTA) for subarachnoid hemorrhage.
Neurosurgeons, neurointerventionalists
Hunt-Hess grade is a key input in the shared decision-making for surgical clipping versus endovascular coiling. Lower-grade patients tolerate early intervention well; higher-grade patients may benefit from delayed intervention after initial stabilization.
Neurosurgeons, neurointensivists, palliative care
Hunt-Hess grade provides a standardized, widely understood framework for discussing expected outcomes with families, including the impact of rebleeding risk and vasospasm on recovery trajectory.
Neuroscience researchers, clinical trialists
Hunt-Hess grade is a required data element for SAH clinical trial enrollment and registry reporting, enabling comparison of patient populations and outcomes across centers.
Neurointensivists, neurocritical care nurses
Higher Hunt-Hess grades indicate greater neurological compromise, guiding decisions about intubation for airway protection, ICP monitoring, external ventricular drain (EVD) placement for hydrocephalus, and vasospasm surveillance intensity.
The original mortality estimates (Grade V ~77%) were from the 1960s–80s era. Modern SAH management — early aneurysm treatment, nimodipine, ICU care, EVD, vasospasm monitoring — has substantially improved outcomes. Grade I 30-day mortality is now approximately 2–5% and Grade V approximately 50–80% at modern stroke centers.
The modified Hunt-Hess scale adds Grade Ia: no acute meningeal or brain reaction but with fixed neurological deficit. This captures patients who had a prior neurological deficit before their SAH, adding nuance to the original grading system.
The World Federation of Neurosurgical Societies (WFNS) scale uses the Glasgow Coma Scale (GCS) score and presence of motor deficit. It is more reproducible and objective than Hunt-Hess because GCS scoring has established criteria. Consider using both scales — WFNS for objectivity and Hunt-Hess for communication with surgeons familiar with the classic system.
CT head without contrast is the first imaging study for suspected SAH. It detects subarachnoid blood in 95%+ of cases when performed within 6 hours of onset. When CT is negative in a patient with thunderclap headache, lumbar puncture for xanthochromia is essential — a CT-negative SAH with positive LP is still SAH.
Xanthochromia (yellowish CSF discoloration from hemoglobin breakdown) is the gold standard for CT-negative SAH. It appears within 2–4 hours of bleeding and persists up to 2 weeks. Spectrophotometry for bilirubin is more sensitive than visual inspection alone.
CTA of the head is the standard first-line study for identifying the causative aneurysm after SAH is confirmed. It has replaced catheter angiography in many centers for initial screening. Digital subtraction angiography (DSA) remains the gold standard and is required when CTA is negative or inconclusive.
Rebleeding is the most immediately life-threatening complication after aneurysmal SAH, occurring in approximately 15–20% of untreated patients within the first day. Securing the aneurysm (clipping or coiling) within 24 hours dramatically reduces this risk. Grade I–III patients should proceed to treatment as soon as feasible.
Nimodipine — a calcium channel blocker — is the only pharmacological treatment proven to improve outcomes after SAH by reducing delayed cerebral ischemia (DCI) from vasospasm. It is standard of care for all grades (21-day course) and reduces poor outcomes by approximately 34% (Pickard et al., BMJ 1989).
Acute hydrocephalus occurs in 15–20% of SAH patients within hours to days. External ventricular drain (EVD) placement reduces ICP and can dramatically improve Hunt-Hess grade (sometimes a Grade IV becomes a Grade II after EVD). Electrolyte monitoring is essential — SIADH and cerebral salt wasting both cause hyponatremia and are common after SAH.
Cerebral vasospasm is the leading cause of delayed morbidity after SAH, typically occurring between days 4 and 14 (peak day 7). Daily transcranial Doppler (TCD) monitoring detects early vasospasm by tracking increased cerebral blood flow velocities. Symptomatic vasospasm is treated with induced hypertension and, if refractory, intra-arterial vasodilators or angioplasty.
Hunt-Hess scale was introduced by Hunt & Hess (J Neurosurg 1968). The modified version is in widespread use. The WFNS SAH Grading Scale (1988) uses GCS and motor deficit for more objective assessment. Nimodipine efficacy in SAH is based on Pickard et al. (BMJ 1989). Current SAH management guidelines: Connolly et al., Stroke 2012; Greenberg & Lantigua, NEJM 2023 review.
Your Hunt & Hess grade reflects the clinical severity of subarachnoid hemorrhage (SAH) at presentation. Grade I indicates a nearly asymptomatic patient or one with only a mild headache and slight nuchal rigidity, carrying approximately 1% surgical mortality. Grade II denotes a moderate-to-severe headache with nuchal rigidity but no neurological deficit beyond a cranial nerve palsy, with roughly 5% surgical mortality. Grade III represents drowsiness, confusion, or mild focal deficit (~19% mortality). Grade IV indicates stupor with moderate-to-severe hemiparesis and early decerebrate posturing (~42% mortality). Grade V signifies deep coma with decerebrate rigidity and a moribund appearance (~77% mortality).
The grade at presentation is one of the strongest predictors of overall outcome after aneurysmal SAH. However, clinical grade can fluctuate — patients may improve or deteriorate due to rebleeding, hydrocephalus, or vasospasm — so serial reassessment is essential.
Use the Hunt & Hess scale immediately upon evaluation of a patient with confirmed or suspected subarachnoid hemorrhage. It is most commonly applied in the emergency department or neurosurgical consultation to communicate clinical severity, guide the urgency of aneurysm intervention (surgical clipping or endovascular coiling), and establish a baseline for prognosis discussions with the patient's family.
Grades I–III are generally considered candidates for early intervention (within 24–72 hours), while Grades IV–V may require stabilization before definitive treatment. The scale is also used in research to stratify SAH patients in clinical trials and outcome studies.
The Hunt & Hess scale is subjective and depends on the examiner's interpretation of clinical status, which can lead to inter-observer variability, particularly between Grades II and III. It does not account for specific neurological deficits, the amount of blood on imaging, or the presence of complications such as hydrocephalus or intraventricular hemorrhage that may independently worsen prognosis.
The scale was developed in 1968 and does not incorporate modern prognostic factors such as patient age, aneurysm location, or the availability of endovascular techniques. It should be used alongside the Fisher CT grade (which assesses vasospasm risk based on blood distribution) and the World Federation of Neurosurgical Societies (WFNS) scale for a more comprehensive assessment. Additionally, a patient's grade can be confounded by sedation, intubation, or metabolic derangements.
For related assessments, see Glasgow Coma Scale and NIH Stroke Scale.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the Glasgow Coma Scale score to assess level of consciousness. Used worldwide in emergency medicine and trauma assessment.
OpenNeurologyCalculate the NIH Stroke Scale (NIHSS) to quantify stroke severity. Mild ≤4, Moderate 5–15, Severe 16–20, Very Severe >20. Guides IV tPA eligibility and acute stroke unit treatment decisions.
Open